User: Guest  Login
Title:

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype

Document type:
Zeitschriftenaufsatz
Author(s):
Orben, Felix; Lankes, Katharina; Schneeweis, Christian; Hassan, Zonera; Jakubowsky, Hannah; Krauß, Lukas; Boniolo, Fabio; Schneider, Carolin; Schäfer, Arlett; Murr, Janine; Schlag, Christoph; Kong, Bo; Öllinger, Rupert; Wang, Chengdong; Beyer, Georg; Mahajan, Ujjwal M.; Xue, Yonggan; Mayerle, Julia; Schmid, Roland M.; Kuster, Bernhard; Rad, Roland; Braun, Christian J.; Wirth, Matthias; Reichert, Maximilian; Saur, Dieter; Schneider, Günter
Abstract:
Systemic therapies for pancreatic ductal adenocarcinoma (PDAC) remain unsatisfactory. Clinical prognosis is particularly poor for tumor subtypes with activating aberrations in the MYC pathway, creating an urgent need for novel therapeutic targets. To unbiasedly find MYC-associated epigenetic dependencies, we conducted a drug screen in pancreatic cancer cell lines. Here, we found that protein arginine N-methyltransferase 5 (PRMT5) inhibitors triggered an MYC-associated dependency. In human and mu...     »
Keywords:
BayBioMS; Cancer; Cell Biology; Oncology; Pharmacology
Journal title:
JCI Insight
Year:
2022
Journal volume:
7
Journal issue:
10
Fulltext / DOI:
doi:10.1172/jci.insight.151353
Publisher:
American Society for Clinical Investigation
E-ISSN:
2379-3708
Date of publication:
23.05.2022
 BibTeX